ReportWire

Tag: Sanofi

  • EU carries out antitrust inspection at premises of pharma Sanofi

    [ad_1]

    The European Commission has carried out unannounced inspections at the premises of French pharmaceutical giant Sanofi in Germany and France, the Brussels-based body said on Tuesday.

    “Unannounced inspections are a preliminary investigative step into suspected anticompetitive practices,” the commission added.

    “The commission has concerns that the inspected company may have violated EU antitrust rules that prohibit abuses of a dominant market position,” as set out in Article 102 of the Treaty on the Functioning of the European Union, it said.

    Advertisement

    Advertisement

    "In particular, the commission is investigating possible exclusionary practices that may amount to anticompetitive disparagement."

    Commission officials were accompanied by their counterparts from national competition authorities.

    Sanofi confirmed the inspections and stated that it is confident that compliance with the relevant rules and regulations will be confirmed. The company is cooperating fully with the European Commission, it said.

    Sanofi did not comment further on the ongoing investigation.

    The commission emphasized that the inspections did not imply any guilt on the part of the company.

    [ad_2]
    Source link

  • Sanofi Plans to Split Consumer-Healthcare, Pharma Businesses — Update

    Sanofi Plans to Split Consumer-Healthcare, Pharma Businesses — Update

    [ad_1]

    By Adria Calatayud

    Sanofi plans to split its consumer-healtchare and pharmaceutical operations, making it the latest big drugmaker to sharpen its focus on prescription medicines by offloading adjacent businesses.
    

    The French company outlined the plan on Friday as part of a strategic update that includes increased investment in its pipeline and a cost-savings program.
    

    

    Sanofi said it is evaluating potential separations options, but believes that the most likely path would be through a capital markets transaction, by creating a listed entity headquartered in France. The split could take place in the fourth quarter of 2024 at the earliest, it said.
    

    The move will allow Sanofi to increase its focus on innovative medicines and vaccines, the company said. The split will create two entities and will enable each to pursue its own strategy, it said.
    

    Sanofi was one of the few big pharma companies that still housed innovative drugs and consumer-healthcare operations under the same roof.
    

    Johnson & Johnson earlier this year spun off consumer-health business Kenvue, which owns brands such as Band-Aid and Tylenol, and GSK last year separated its Haleon consumer arm. Other pharma giants such as Novartis and Pfizer made similar moves in recent years.
    

    The plan remains subject to market conditions and consultation with social partners. Sanofi’s consumer-healthcare business is present in 150 countries and employs more than 11,000 people, it said.
    

    Write to Adria Calatayud at adria.calatayud@dowjones.com
    

    

    

    [ad_2]
    

    Source link